JonesTrading analyst Justin Walsh has reiterated their bullish stance on RAPP stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Justin Walsh has given his Buy rating due to a combination of factors including the promising results of Rapport Therapeutics’ lead asset, RAP-219, in treating refractory focal epilepsy. The Phase IIa trial demonstrated favorable efficacy and safety, which supports the advancement of RAP-219 into Phase III trials. Additionally, the company is well-positioned financially, with a strong cash reserve expected to fund operations into the second half of 2029.
Walsh is optimistic about the potential of RAP technology to be both clinically effective and commercially viable across multiple central nervous system indications. The strategic focus on biomarker-informed trial designs is anticipated to create a robust pipeline, driving long-term value for shareholders. The upcoming milestones, such as the start of Phase III trials and updates on other indications, further bolster confidence in the company’s growth prospects.
In another report released today, Citizens JMP also maintained a Buy rating on the stock with a $80.00 price target.